Insmed reports positive 12-month data for investigational PAH therapy TPIP

Filed July 16, 2026 · Period ending July 16, 2026 · ~1 min read

Key Changes

• high

  12-month open-label extension study showed sustained improvements in exercise capacity (+55.7m 6MWD), 60% reduction in cardiac stress biomarker NT-proBNP, and ~65% of patients achieving low mortality risk status; patients switching from placebo achieved similar outcomes.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• high

  Safety profile remained favorable with 91% patient completion through 12 months; 89% experienced treatment-emergent adverse events, mostly mild-to-moderate, with only 7.7% discontinuing due to adverse events and four deaths none considered treatment-related.

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• high

  Phase 3 PAH trial (PALM-PAH) enrollment progressing; additional Phase 3 programs for pulmonary hypertension in interstitial lung disease (sites screening), progressive pulmonary fibrosis (initiation expected 2H 2026), and idiopathic pulmonary fibrosis (initiation expected 1H 2027).

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →